ES2421596T3 - Desaminasa inducida por activación (AID) - Google Patents

Desaminasa inducida por activación (AID)

Info

Publication number
ES2421596T3
ES2421596T3 ES03722838T ES03722838T ES2421596T3 ES 2421596 T3 ES2421596 T3 ES 2421596T3 ES 03722838 T ES03722838 T ES 03722838T ES 03722838 T ES03722838 T ES 03722838T ES 2421596 T3 ES2421596 T3 ES 2421596T3
Authority
ES
Spain
Prior art keywords
gene product
aid
desired activity
activation
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03722838T
Other languages
English (en)
Inventor
S C Petesersen-Mahr
R S Harris
M S Neuberger
R C L Beale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0210755A external-priority patent/GB0210755D0/en
Priority claimed from GB0213751A external-priority patent/GB0213751D0/en
Priority claimed from GB0217519A external-priority patent/GB0217519D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2421596T3 publication Critical patent/ES2421596T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un método para preparar un producto génico mutado que tiene una actividad deseada que puede distinguirsecualitativa o cuantitativamente de la actividad del producto génico no mutado correspondiente, que comprende lasetapas de: a) expresión de un ácido nucleico que codifica para dicho producto génico no mutado en células procariotas, en elque las células procariotas han sido modificadas para expresar la citidina desaminasa inducida por activación (AID) ouna proteína de la familia de proteínas APOBEC capaces de mutar el ADN; b) selección de una o más de las células procariotas que expresan un mutante del producto génico, teniendo elmutante la actividad deseada; e c) identificación del producto génico mutado que tiene la actividad deseada.
ES03722838T 2002-05-10 2003-05-09 Desaminasa inducida por activación (AID) Expired - Lifetime ES2421596T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0210755A GB0210755D0 (en) 2002-05-10 2002-05-10 Aid
GB0213751A GB0213751D0 (en) 2002-06-14 2002-06-14 Aid
GB0217519A GB0217519D0 (en) 2002-07-29 2002-07-29 Aid
PCT/GB2003/002002 WO2003095636A2 (en) 2002-05-10 2003-05-09 Activation induced deaminase (aid)

Publications (1)

Publication Number Publication Date
ES2421596T3 true ES2421596T3 (es) 2013-09-04

Family

ID=29424146

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03722838T Expired - Lifetime ES2421596T3 (es) 2002-05-10 2003-05-09 Desaminasa inducida por activación (AID)

Country Status (6)

Country Link
US (3) US7820442B2 (es)
EP (1) EP1506288B1 (es)
AU (1) AU2003229998A1 (es)
DK (1) DK1506288T3 (es)
ES (1) ES2421596T3 (es)
WO (1) WO2003095636A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122339B2 (en) * 1998-10-09 2006-10-17 Medical Research Council Method for generating diversity
AU2003229998A1 (en) * 2002-05-10 2003-11-11 Medical Research Council Activation induced deaminase (aid)
US7776599B2 (en) 2002-07-30 2010-08-17 Riken Method of enhancing homologous recombination of somatic cells and method of constructing specific antibody
DE602004012406T2 (de) 2003-05-23 2009-04-30 Oregon Health & Science University, Portland Verfahren zur identifikation von inhibitoren
WO2007002372A2 (en) * 2005-06-24 2007-01-04 Regents Of The University Of Minnesota Using cytosine deaminases to diminish retroelement transfer from pigs to humans
GB0607063D0 (en) * 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
US20090075378A1 (en) 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
CA2738635C (en) 2008-09-05 2019-12-31 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
DK2414507T3 (da) * 2009-04-03 2014-08-25 Medical Res Council Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder
US20120309011A1 (en) * 2009-11-02 2012-12-06 Salk Institute For Biological Studies Targeting of modifying enzymes for protein evolution
US20110104787A1 (en) * 2009-11-05 2011-05-05 President And Fellows Of Harvard College Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
AU2011348204B2 (en) 2010-12-22 2017-03-02 President And Fellows Of Harvard College Continuous directed evolution
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
EP3097196B1 (en) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negative selection and stringency modulation in continuous evolution systems
US20160369258A1 (en) * 2014-03-11 2016-12-22 University Of Washington Restricting nuclear protein to specific phases of the cell cycle
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
WO2016073660A1 (en) * 2014-11-06 2016-05-12 Albert Einstein College Of Medicine, Inc. Methods to accelerate antibody diversification
US20180072793A1 (en) * 2015-04-09 2018-03-15 Health Research, Inc. Apobec3a cytidine deaminase induced rna editing
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
EP3307089B1 (en) * 2015-06-15 2018-12-05 Unilever N.V. Food product
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College EVOLUTION OF ARNT SYNTHÉTASES
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
EP3697906A1 (en) 2017-10-16 2020-08-26 The Broad Institute, Inc. Uses of adenosine base editors
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
AU3330700A (en) * 1999-03-29 2000-10-16 Tasuku Honjo Novel cytidine deaminase
US20050095712A1 (en) * 2002-01-17 2005-05-05 Alberto Martin Mutations caused by activation-induced cytidine deaminase
AU2003229998A1 (en) * 2002-05-10 2003-11-11 Medical Research Council Activation induced deaminase (aid)

Also Published As

Publication number Publication date
US8288160B2 (en) 2012-10-16
US20110136922A1 (en) 2011-06-09
US20060019262A1 (en) 2006-01-26
AU2003229998A1 (en) 2003-11-11
DK1506288T3 (da) 2013-07-22
EP1506288A2 (en) 2005-02-16
EP1506288B1 (en) 2013-04-17
AU2003229998A8 (en) 2003-11-11
US7820442B2 (en) 2010-10-26
WO2003095636A3 (en) 2004-02-12
US20130059931A1 (en) 2013-03-07
WO2003095636A2 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
ES2421596T3 (es) Desaminasa inducida por activación (AID)
Zetsche et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system
Kamath et al. Genome-wide RNAi screening in Caenorhabditis elegans
Miranda et al. Evolution of the genetic code in yeasts
ATE453728T1 (de) Screening mutagenisierter populationen mit hohem durchsatz
Thompson et al. The future of multiplexed eukaryotic genome engineering
Yaung et al. CRISPR/Cas9-mediated phage resistance is not impeded by the DNA modifications of phage T4
Kostallas et al. Substrate profiling of tobacco etch virus protease using a novel fluorescence-assisted whole-cell assay
KR20180043369A (ko) 뉴클레아제 dsb의 완전한 호출 및 시퀀싱(find-seq)
HK1082761A1 (en) Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
WO2004039953A3 (en) Array oligomer synthesis and use.
Kick et al. CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials
WO2002074979A3 (en) Expression profiles and methods of use
ES2155702T3 (es) Construcciones expresivas halteroformes para la terapia genetica.
WO2007040592A8 (en) Making nucleic acid sequences in parallel and use
Lindner et al. DNA libraries for the construction of phage libraries: Statistical and structural requirements and synthetic methods
Moir-Meyer et al. Robust CRISPR/Cas9 genome editing of the HUDEP-2 erythroid precursor line using plasmids and single-stranded oligonucleotide donors
Reuven et al. Recruitment of DNA repair MRN complex by intrinsically disordered protein domain fused to Cas9 improves efficiency of CRISPR-mediated genome editing
Lin et al. Engineering the direct repeat sequence of crRNA for optimization of FnCpf1-mediated genome editing in human cells
McKenney et al. From prebiotics to probiotics: The evolution and functions of tRNA modifications
WO2005079367A3 (en) Schizochytrium fatty acid synthase (fas) and products and methods related thereto
Demongeot et al. Emergence of a “cyclosome” in a primitive network capable of building “infinite” proteins
GB2409457B (en) Method to generate or determine nucleic acid tags corresponding to the terminal ends of DNA molecules using sequence analysis of gene expression(terminal SAGE
Xin et al. Double-check base editing for efficient A to G conversions
Tálas et al. A method for characterizing Cas9 variants via a one-million target sequence library of self-targeting sgRNAs